Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 242

1.

Toward Isolating Reward Changes in Diet-Induced Obesity: A Demand Analysis.

Batten SR, Hicks KB, Dwoskin LP, Beckmann JS.

Physiol Behav. 2019 Oct 31:112729. doi: 10.1016/j.physbeh.2019.112729. [Epub ahead of print]

PMID:
31678579
2.

GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine.

Lee NR, Zheng G, Leggas M, Janganati V, Nickell JR, Crooks PA, Bardo MT, Dwoskin LP.

J Pharmacol Exp Ther. 2019 Nov;371(2):526-543. doi: 10.1124/jpet.119.258699. Epub 2019 Aug 14.

PMID:
31413138
3.

Effects of methamphetamine isomers on d-methamphetamine self-administration and food-maintained responding in male rats.

Bardo MT, Denehy ED, Hammerslag LR, Dwoskin LP, Blough BE, Landavazo A, Bergman J, Kohut SJ.

Psychopharmacology (Berl). 2019 Jul 26. doi: 10.1007/s00213-019-05327-8. [Epub ahead of print]

PMID:
31346628
4.

Predicting substance use disorder using long-term attention deficit hyperactivity disorder medication records in Truven.

Fouladvand S, Hankosky ER, Bush H, Chen J, Dwoskin LP, Freeman PR, Henderson DW, Kantak K, Talbert J, Tao S, Zhang GQ.

Health Informatics J. 2019 May 19:1460458219844075. doi: 10.1177/1460458219844075. [Epub ahead of print]

PMID:
31106686
5.

Semisynthetic aurones inhibit tubulin polymerization at the colchicine-binding site and repress PC-3 tumor xenografts in nude mice and myc-induced T-ALL in zebrafish.

Xie Y, Kril LM, Yu T, Zhang W, Frasinyuk MS, Bondarenko SP, Kondratyuk KM, Hausman E, Martin ZM, Wyrebek PP, Liu X, Deaciuc A, Dwoskin LP, Chen J, Zhu H, Zhan CG, Sviripa VM, Blackburn J, Watt DS, Liu C.

Sci Rep. 2019 Apr 23;9(1):6439. doi: 10.1038/s41598-019-42917-0.

6.

Retrospective analysis of health claims to evaluate pharmacotherapies with potential for repurposing: Association of bupropion and stimulant use disorder remission.

Hankosky ER, Bush HM, Dwoskin LP, Harris DR, Henderson DW, Zhang GQ, Freeman PR, Talbert JC.

AMIA Annu Symp Proc. 2018 Dec 5;2018:1292-1299. eCollection 2018.

7.

N,N'-diaryl-bishydrazones in a biphenyl platform: Broad spectrum antifungal agents.

Thamban Chandrika N, Dennis EK, Shrestha SK, Ngo HX, Green KD, Kwiatkowski S, Deaciuc AG, Dwoskin LP, Watt DS, Garneau-Tsodikova S.

Eur J Med Chem. 2019 Feb 15;164:273-281. doi: 10.1016/j.ejmech.2018.12.042. Epub 2018 Dec 18.

PMID:
30597328
8.

Muscarinic agonist, (±)-quinuclidin-3-yl-(4-fluorophenethyl)(phenyl)carbamate: High affinity, but low subtype selectivity for human M1 - M5 muscarinic acetylcholine receptors.

Lee NR, Gujarathi S, Bommagani S, Siripurapu K, Zheng G, Dwoskin LP.

Bioorg Med Chem Lett. 2019 Feb 1;29(3):471-476. doi: 10.1016/j.bmcl.2018.12.022. Epub 2018 Dec 11.

PMID:
30554957
9.

An improved model of ethanol and nicotine co-use in female P rats: Effects of naltrexone, varenicline, and the selective nicotinic α6β2* antagonist r-bPiDI.

Maggio SE, Saunders MA, Nixon K, Prendergast MA, Zheng G, Crooks PA, Dwoskin LP, Bell RL, Bardo MT.

Drug Alcohol Depend. 2018 Dec 1;193:154-161. doi: 10.1016/j.drugalcdep.2018.09.008. Epub 2018 Oct 17.

PMID:
30384323
10.

Predicting Substance Use Disorder in ADHD Patients using Long-Short Term Memory Model.

Fouladvand S, Hankosky ER, Henderson DW, Bush H, Chen J, Dwoskin LP, Freeman PR, Kantak K, Talbert J, Tao S, Zhang GQ.

2018 IEEE Int Conf Healthc Inform Workshop (2018). 2018 Jun;2018:49-50. doi: 10.1109/ICHI-W.2018.00014. Epub 2018 Jul 19.

11.

Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats.

Maggio SE, Saunders MA, Baxter TA, Nixon K, Prendergast MA, Zheng G, Crooks P, Dwoskin LP, Slack RD, Newman AH, Bell RL, Bardo MT.

Psychopharmacology (Berl). 2018 May;235(5):1439-1453. doi: 10.1007/s00213-018-4853-4. Epub 2018 Feb 18.

12.

New Scaffold for Lead Compounds to Treat Methamphetamine Use Disorders.

Lee NR, Zheng G, Crooks PA, Bardo MT, Dwoskin LP.

AAPS J. 2018 Feb 9;20(2):29. doi: 10.1208/s12248-018-0192-y.

PMID:
29427069
13.

Competency, Programming, and Emerging Innovation in Graduate Education within Schools of Pharmacy: The Report of the 2016-2017 Research and Graduate Affairs Committee.

Poloyac SM, Block KF, Cavanaugh JE, Dwoskin LP, Melchert RB, Nemire RE, O'Donnell JM, Priefer R, Touchette DR.

Am J Pharm Educ. 2017 Oct;81(8):S11. doi: 10.5688/ajpeS11.

14.

Fluoroethoxy-1,4-diphenethylpiperidine and piperazine derivatives: Potent and selective inhibitors of [3H]dopamine uptake at the vesicular monoamine transporter-2.

Hankosky ER, Joolakanti SR, Nickell JR, Janganati V, Dwoskin LP, Crooks PA.

Bioorg Med Chem Lett. 2017 Dec 15;27(24):5467-5472. doi: 10.1016/j.bmcl.2017.10.039. Epub 2017 Oct 20.

15.

Varenicline and GZ-793A differentially decrease methamphetamine self-administration under a multiple schedule of reinforcement in rats.

Kangiser MM, Dwoskin LP, Zheng G, Crooks PA, Stairs DJ.

Behav Pharmacol. 2018 Feb;29(1):87-97. doi: 10.1097/FBP.0000000000000340.

16.

Tobacco's minor alkaloids: Effects on place conditioning and nucleus accumbens dopamine release in adult and adolescent rats.

Marusich JA, Darna M, Wilson AG, Denehy ED, Ebben A, Deaciuc AG, Dwoskin LP, Bardo MT, Lefever TW, Wiley JL, Reissig CJ, Jackson KJ.

Eur J Pharmacol. 2017 Nov 5;814:196-206. doi: 10.1016/j.ejphar.2017.08.029. Epub 2017 Aug 26.

17.

Blockade of α2-adrenergic receptors in prelimbic cortex: impact on cocaine self-administration in adult spontaneously hypertensive rats following adolescent atomoxetine treatment.

Baskin BM, Nic Dhonnchadha BÁ, Dwoskin LP, Kantak KM.

Psychopharmacology (Berl). 2017 Oct;234(19):2897-2909. doi: 10.1007/s00213-017-4681-y. Epub 2017 Jul 20.

18.

Nicotinic Acetylcholine Receptors as Targets for Tobacco Cessation Therapeutics: Cutting-Edge Methodologies to Understand Receptor Assembly and Trafficking.

Fox-Loe AM, Dwoskin LP, Richards CI.

Neuromethods. 2016;117:119-132. doi: 10.1007/978-1-4939-3768-4_7. Epub 2016 Sep 30.

19.

GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2.

Nickell JR, Siripurapu KB, Horton DB, Zheng G, Crooks PA, Dwoskin LP.

Eur J Pharmacol. 2017 Jan 15;795:143-149. doi: 10.1016/j.ejphar.2016.12.016. Epub 2016 Dec 13.

PMID:
27986625
20.

The effect of sazetidine-A and other nicotinic ligands on nicotine controlled goal-tracking in female and male rats.

Charntikov S, Falco AM, Fink K, Dwoskin LP, Bevins RA.

Neuropharmacology. 2017 Feb;113(Pt A):354-366. doi: 10.1016/j.neuropharm.2016.10.014. Epub 2016 Oct 17.

21.

Obesity: Current and potential pharmacotherapeutics and targets.

Narayanaswami V, Dwoskin LP.

Pharmacol Ther. 2017 Feb;170:116-147. doi: 10.1016/j.pharmthera.2016.10.015. Epub 2016 Oct 20. Review.

22.

Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents.

Shrestha SK, Kril LM, Green KD, Kwiatkowski S, Sviripa VM, Nickell JR, Dwoskin LP, Watt DS, Garneau-Tsodikova S.

Bioorg Med Chem. 2017 Jan 1;25(1):58-66. doi: 10.1016/j.bmc.2016.10.009. Epub 2016 Oct 10.

23.

Adolescent d-amphetamine treatment in a rodent model of attention deficit/hyperactivity disorder: impact on cocaine abuse vulnerability in adulthood.

Jordan CJ, Lemay C, Dwoskin LP, Kantak KM.

Psychopharmacology (Berl). 2016 Dec;233(23-24):3891-3903. Epub 2016 Sep 6.

24.

Synthesis and in vitro evaluation of water-soluble 1,4-diphenethylpiperazine analogs as novel inhibitors of the vesicular monoamine transporter-2.

Nickell JR, Culver JP, Janganati V, Zheng G, Dwoskin LP, Crooks PA.

Bioorg Med Chem Lett. 2016 Sep 15;26(18):4441-4445. doi: 10.1016/j.bmcl.2016.08.001. Epub 2016 Aug 2.

25.

1,4-Diphenalkylpiperidines: A new scaffold for the design of potent inhibitors of the vesicular monoamine transporter-2.

Nickell JR, Culver JP, Janganati V, Zheng G, Dwoskin LP, Crooks PA.

Bioorg Med Chem Lett. 2016 Jul 1;26(13):2997-3000. doi: 10.1016/j.bmcl.2016.05.025. Epub 2016 May 10.

26.

Lobelane analogues containing 4-hydroxy and 4-(2-fluoroethoxy) aromatic substituents: Potent and selective inhibitors of [(3)H]dopamine uptake at the vesicular monoamine transporter-2.

Joolakanti SR, Nickell JR, Janganati V, Zheng G, Dwoskin LP, Crooks PA.

Bioorg Med Chem Lett. 2016 May 15;26(10):2422-2427. doi: 10.1016/j.bmcl.2016.03.119. Epub 2016 Apr 1.

27.

Necessity for research directed at stimulant type and treatment-onset age to access the impact of medication on drug abuse vulnerability in teenagers with ADHD.

Kantak KM, Dwoskin LP.

Pharmacol Biochem Behav. 2016 Jun;145:24-6. doi: 10.1016/j.pbb.2016.03.009. Epub 2016 Mar 22. No abstract available.

28.

Synthesis of O- and N-alkylated products of 1,2,3,4-tetrahydrobenzo[c][2,7]naphthyrin-5(6H)-one.

Bommagani S, Lee NR, Zhang X, Dwoskin LP, Zheng G.

Tetrahedron Lett. 2015 Nov 18;56(46):6472-6474.

29.

Adolescent methylphenidate treatment differentially alters adult impulsivity and hyperactivity in the Spontaneously Hypertensive Rat model of ADHD.

Somkuwar SS, Kantak KM, Bardo MT, Dwoskin LP.

Pharmacol Biochem Behav. 2016 Feb;141:66-77. doi: 10.1016/j.pbb.2015.12.002. Epub 2015 Dec 2.

30.

Individual differences in impulsive action and dopamine transporter function in rat orbitofrontal cortex.

Yates JR, Darna M, Beckmann JS, Dwoskin LP, Bardo MT.

Neuroscience. 2016 Jan 28;313:122-9. doi: 10.1016/j.neuroscience.2015.11.033. Epub 2015 Nov 23.

31.

Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse.

Van Skike CE, Maggio SE, Reynolds AR, Casey EM, Bardo MT, Dwoskin LP, Prendergast MA, Nixon K.

Prog Neuropsychopharmacol Biol Psychiatry. 2016 Feb 4;65:269-87. doi: 10.1016/j.pnpbp.2015.11.004. Epub 2015 Nov 12. Review.

32.

Par-4 secretion: stoichiometry of 3-arylquinoline binding to vimentin.

Sviripa VM, Burikhanov R, Obiero JM, Yuan Y, Nickell JR, Dwoskin LP, Zhan CG, Liu C, Tsodikov OV, Rangnekar VM, Watt DS.

Org Biomol Chem. 2016 Jan 7;14(1):74-84. doi: 10.1039/c5ob01980j.

33.

Muscarinic acetylcholine receptor binding affinities of pethidine analogs.

Lee NR, Zhang X, Darna M, Dwoskin LP, Zheng G.

Bioorg Med Chem Lett. 2015 Nov 15;25(22):5032-5. doi: 10.1016/j.bmcl.2015.10.029. Epub 2015 Oct 19.

34.

Adolescent D-amphetamine treatment in a rodent model of ADHD: Pro-cognitive effects in adolescence without an impact on cocaine cue reactivity in adulthood.

Jordan CJ, Taylor DM, Dwoskin LP, Kantak KM.

Behav Brain Res. 2016 Jan 15;297:165-79. doi: 10.1016/j.bbr.2015.10.017. Epub 2015 Oct 20.

35.

The effect of switching pharmacological intervention during extinction on nicotine-evoked conditioned responding in rats.

Pittenger ST, Zeplin LC, Dwoskin LP, Bevins RA.

Psychopharmacology (Berl). 2015 Dec;232(23):4347-58. doi: 10.1007/s00213-015-4067-y. Epub 2015 Sep 14.

36.

r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement.

Beckmann JS, Meyer AC, Pivavarchyk M, Horton DB, Zheng G, Smith AM, Wooters TE, McIntosh JM, Crooks PA, Bardo MT, Dwoskin LP.

Neurochem Res. 2015 Oct;40(10):2121-30. doi: 10.1007/s11064-015-1680-4. Epub 2015 Jul 31.

37.

Role of serotonin transporter function in rat orbitofrontal cortex in impulsive choice.

Darna M, Chow JJ, Yates JR, Charnigo RJ, Beckmann JS, Bardo MT, Dwoskin LP.

Behav Brain Res. 2015 Oct 15;293:134-42. doi: 10.1016/j.bbr.2015.07.025. Epub 2015 Jul 13.

38.

Dissociable roles of dopamine and serotonin transporter function in a rat model of negative urgency.

Yates JR, Darna M, Gipson CD, Dwoskin LP, Bardo MT.

Behav Brain Res. 2015 Sep 15;291:201-208. doi: 10.1016/j.bbr.2015.05.023. Epub 2015 May 21.

39.

Quinolyl analogues of norlobelane: novel potent inhibitors of [(3)H]dihydrotetrabenazine binding and [(3)H]dopamine uptake at the vesicular monoamine transporter-2.

Ding D, Nickell JR, Dwoskin LP, Crooks PA.

Bioorg Med Chem Lett. 2015 Jul 1;25(13):2613-6. doi: 10.1016/j.bmcl.2015.04.105. Epub 2015 May 9.

40.

Pharmacologically distinct nicotinic acetylcholine receptors drive efferent-mediated excitation in calyx-bearing vestibular afferents.

Holt JC, Kewin K, Jordan PM, Cameron P, Klapczynski M, McIntosh JM, Crooks PA, Dwoskin LP, Lysakowski A.

J Neurosci. 2015 Feb 25;35(8):3625-43. doi: 10.1523/JNEUROSCI.3388-14.2015.

41.

Effect of methylphenidate treatment during adolescence on norepinephrine transporter function in orbitofrontal cortex in a rat model of attention deficit hyperactivity disorder.

Somkuwar SS, Kantak KM, Dwoskin LP.

J Neurosci Methods. 2015 Aug 30;252:55-63. doi: 10.1016/j.jneumeth.2015.02.002. Epub 2015 Feb 11.

42.

Methylphenidate treatment beyond adolescence maintains increased cocaine self-administration in the spontaneously hypertensive rat model of attention deficit/hyperactivity disorder.

Baskin BM, Dwoskin LP, Kantak KM.

Pharmacol Biochem Behav. 2015 Apr;131:51-6. doi: 10.1016/j.pbb.2015.01.019. Epub 2015 Jan 31.

43.

Effect of environmental enrichment on dopamine and serotonin transporters and glutamate neurotransmission in medial prefrontal and orbitofrontal cortex.

Darna M, Beckmann JS, Gipson CD, Bardo MT, Dwoskin LP.

Brain Res. 2015 Mar 2;1599:115-25. doi: 10.1016/j.brainres.2014.12.034. Epub 2014 Dec 20.

44.

2',6'-Dihalostyrylanilines, pyridines, and pyrimidines for the inhibition of the catalytic subunit of methionine S-adenosyltransferase-2.

Sviripa VM, Zhang W, Balia AG, Tsodikov OV, Nickell JR, Gizard F, Yu T, Lee EY, Dwoskin LP, Liu C, Watt DS.

J Med Chem. 2014 Jul 24;57(14):6083-91. doi: 10.1021/jm5004864. Epub 2014 Jul 9.

45.

Scientific overview: 2013 BBC plenary symposium on tobacco addiction.

De Biasi M, McLaughlin I, Perez EE, Crooks PA, Dwoskin LP, Bardo MT, Pentel PR, Hatsukami D.

Drug Alcohol Depend. 2014 Aug 1;141:107-17. doi: 10.1016/j.drugalcdep.2014.05.013. Epub 2014 Jun 2. Erratum in: Drug Alcohol Depend. 2014 Nov 1;144:290.

46.

Environmental enrichment reduces methamphetamine cue-induced reinstatement but does not alter methamphetamine reward or VMAT2 function.

Hofford RS, Darna M, Wilmouth CE, Dwoskin LP, Bardo MT.

Behav Brain Res. 2014 Aug 15;270:151-8. doi: 10.1016/j.bbr.2014.05.007. Epub 2014 May 10.

47.

Cocaine-seeking behavior in a genetic model of attention-deficit/hyperactivity disorder following adolescent methylphenidate or atomoxetine treatments.

Jordan CJ, Harvey RC, Baskin BB, Dwoskin LP, Kantak KM.

Drug Alcohol Depend. 2014 Jul 1;140:25-32. doi: 10.1016/j.drugalcdep.2014.04.020. Epub 2014 Apr 28.

48.

Effects of dopamine D1 receptor blockade in the prelimbic prefrontal cortex or lateral dorsal striatum on frontostriatal function in Wistar and Spontaneously Hypertensive Rats.

Gauthier JM, Tassin DH, Dwoskin LP, Kantak KM.

Behav Brain Res. 2014 Jul 15;268:229-38. doi: 10.1016/j.bbr.2014.04.018. Epub 2014 Apr 19.

49.

Efficient synthesis of cis-2,6-di-(2- quinolylpiperidine).

Ding D, Dwoskin LP, Crooks PA.

Tetrahedron Lett. 2013 Sep 18;54(38):5211-5213.

50.

Preface. Emerging targets and therapeutics in the treatment of psychostimulant abuse.

Dwoskin LP.

Adv Pharmacol. 2014;69:xi-xiii. doi: 10.1016/B978-0-12-420118-7.10000-9. No abstract available.

PMID:
24484989

Supplemental Content

Loading ...
Support Center